Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China · Delayed Price · Currency is CNY 5.46
+0.05 (0.92%)
Sep 10, 2026, 3:04 PM CST
SHE:002581 Revenue
Shandong Sinobioway Biomedicine had revenue of 50.17M CNY in the quarter ending June 30, 2026, with 41.56% growth. This brings the company's revenue in the last twelve months to 298.07M, up 35.24% year-over-year. In the year 2025, Shandong Sinobioway Biomedicine had annual revenue of 274.81M, down -23.75%.
Revenue (ttm)
298.07M
Revenue Growth
+35.24%
P/S Ratio
11.97
Revenue / Employee
605.83K
Employees
492
Market Cap
3.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 274.81M | -85.60M | -23.75% |
| Dec 31, 2024 | 360.41M | -69.39M | -16.14% |
| Dec 31, 2023 | 429.79M | 72.71M | 20.36% |
| Jan 1, 2023 | 357.08M | -45.63M | -11.33% |
| Jan 1, 2022 | 402.71M | 125.88M | 45.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Tibet AIM Pharm. | 684.45M |
| Lionco Pharmaceutical Group | 408.33M |